Correction: HDAC inhibitor AR-42 decreases CD44 expression and sensitizes myeloma cells to lenalidomide

Affiliations

• ¹ Department of Internal Medicine, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
• ² Department of Internal Medicine, Oncology/Hematology Fellowship, The Ohio State University, Columbus, OH, USA.
• ³ Lymphoma and Genomics Research Program, IOR Institute of Oncology Research, Bellinzona, Switzerland.
• ⁴ Department of Internal Medicine, Biomedical Sciences Graduate Program, Comprehensive Cancer Center, The Ohio State University, Columbus, OH, USA.
• ⁵ Present Address: Sanford Burnham Prebys Medical Discovery Insitute, La Jolla, CA, USA.
• ⁶ Department of Internal Medicine, Biosystems Analysis, LTTA, Department of Morphology, Surgery and Experimental Medicine, Università degli Studi, Ferrara, Italy.
• ⁷ Department of Neurological Surgery, Dardinger Laboratory for Neuro-oncology and Neurosciences, The Ohio State University Medical Center, Columbus, Ohio, USA.
• ⁸ Department of Biomedical Informatics, Center for Biostatistics, The Ohio State University, Columbus, OH, USA.
• ⁹ Department of Internal Medicine, Division of Hematology, The Ohio State University, Columbus, OH, USA.